1de Morais SM,Wilkinson GR,Blaisdell J,et al.Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese[J].Mol Pharmacol,1994; 46:594 -598.. 被引量：1
2Furuta T,Ohashi K,Kosuge K,et al.CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans[J].Clin Pharmacol Ther,1999; 65:552-561. 被引量：1
3Shirai N,Furuta T,Moriyama Y,et al.Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH[J].Aliment Pharnacol Ther,2001; 15:1929-1937. 被引量：1
4Shimatani T,Inoue M,Kuroiwa T,et al.Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes,compared with omeprazole 20 mg and lafutidine 20 mg,a new H2 -receptor antagonist[J].Aliment Pharmacol Ther,2003;18:1149-1157. 被引量：1
5Yamada S,Onda M,Kato S,et al.Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations[J].J Gastroenterol,2001 ;36:669-672. 被引量：1
6Sohn DR,Kobayashi K,Chiba K,et al.Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4-hydroxylation recruited from an Oriental population[J].J Pharmacol Exp Ther,1992; 262:1195-1202. 被引量：1
7Ieiri I,Kubota T,Urae A,et al.Pharuaeokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles,CYP2C19M1 in exon 5 and CYP2C19M2 in exon 4,in Japanese subjects[J].Clin Pharmacol Ther,1996; 59:647-653. 被引量：1
8Tytgat GN.Shortcomings of the first-generation proton pump inhibitors[J].Eur J Gastroenterol Hepatol,2001; 13(Suppl.1):S29 -33. 被引量：1
9Sakai T,Aoyama N,Kita T,et al.CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects[J].Pharm Res,2001 ;18:721 -727. 被引量：1
